Posted by Michael Wonder on 27 Apr 2018
Agenda for the July 2018 PBAC meeting
27 April 2018 - The agenda for the July 2018 PBAC meeting is now available.
The PBAC is set to consider 57 (30 major, 27 minor) submissions.
The Committee will also consider six reports from the Drug Utilisation Subcommittee (DUSC) for medicines for:
- Age-related macular degeneration & macular oedema (3 medicines)
- Malignant melanoma (7 medicines)
- Attention deficit-hyperactivity disorder (5 medicines)
- Muscle spasticity/blepharospasm (3 medicines)
- Gastro-oesophageal reflux disease (5 medicines)
- Fungal infection (1 medicine)
13 (23%) of the 57 submissions are for a new medicine.
17 (30%) of the 57 submissions are resubmissions; most are for a new medicine or a new indication.
Just under a quarter of all submissions are for oncology medicines.
MSD is the leading applicant with eight submissions (6 major, 2 minor).
All 57 submissions have been uploaded to the MAESTrO Database; all users should be able to conduct discrete analyses of the submissions as they please.
Further results of MAESTrO Databases's analysis of the agenda can be found here.
Further insights from the agenda will appear in tomorrow's edition of MAESTrO Daily.
